Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Denali Therapeutics Inc (NQ: DNLI ) 23.53 +2.07 (+9.65%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 3,222,048 Open 21.62 Bid (Size) 23.15 (1) Ask (Size) 23.75 (1) Prev. Close 21.46 Today's Range 21.25 - 23.70 52wk Range 14.56 - 29.22 Shares Outstanding 121,640,069 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Denali Therapeutics Stock Gets Technical Rating Upgrade July 16, 2024 Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating Via Investor's Business Daily 3 Longevity Stocks to Buy for Anti-Aging Breakthroughs July 08, 2024 Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery. Via InvestorPlace Performance YTD +10.00% +10.00% 1 Month +2.71% +2.71% 3 Month +47.15% +47.15% 6 Month +35.85% +35.85% 1 Year -17.15% -17.15% More News Read More Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday June 03, 2024 Via Benzinga Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies June 03, 2024 From Denali Therapeutics Inc. Via GlobeNewswire 4 Analysts Assess Denali Therapeutics: What You Need To Know February 28, 2024 Via Benzinga Denali Therapeutics: Q4 Earnings Insights February 27, 2024 Via Benzinga Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday May 08, 2024 Via Benzinga DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024 May 07, 2024 Via InvestorPlace Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights May 07, 2024 From Denali Therapeutics Inc. Via GlobeNewswire The Latest Analyst Ratings for Denali Therapeutics December 13, 2023 Via Benzinga Where Denali Therapeutics Stands With Analysts November 08, 2023 Via Benzinga Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial May 01, 2024 From Denali Therapeutics Inc. Via GlobeNewswire To the Moon and Beyond: 7 Stocks With Cosmic Potential March 14, 2024 Via InvestorPlace Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know February 29, 2024 Via Benzinga Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday February 27, 2024 Via Benzinga Topics Stocks Exposures US Equities Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session February 27, 2024 Via Benzinga Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights February 27, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces $500 million Private Placement Equity Financing February 27, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst February 12, 2024 Via Benzinga 3 Biotech Stocks to Buy for the Next Bull Run: February 2024 February 08, 2024 Via InvestorPlace Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™ February 07, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™ February 01, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases January 08, 2024 From Denali Therapeutics Inc. Via GlobeNewswire 3 Biotech Stocks at the Forefront of the Quest for Eternal Youth January 02, 2024 Via InvestorPlace Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights November 07, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.